{"analyses":[{"ciPctValue":"95","groupDescription":"Overall (Complete + Partial Remission)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0001","statisticalMethod":"Fisher Exact"},{"ciPctValue":"95","groupDescription":"Complete remission","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0150","statisticalMethod":"Fisher Exact"},{"ciPctValue":"95","groupDescription":"Partial Remission","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0094","statisticalMethod":"Fisher Exact"},{"ciPctValue":"95","groupDescription":"Stable Disease","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.3297","statisticalMethod":"Fisher Exact"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"21"}]}],"title":"Overall (Complete + Partial Remission)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"14"}]}],"title":"Complete Remission"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"7"}]}],"title":"Partial Remission"},{"categories":[{"measurements":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"65"}]}],"title":"Stable Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"179"}],"units":"Participants"}],"description":"Investigator determined responses followed IWG criteria for\n\n* complete remission(CR): repeat bone marrow show \\<5% myeloblasts, and peripheral blood evaluations lasting \\>=2 months of hemoglobin(\\>110 g/L), neutrophils(\\>=1.5x10\\^9/L), platelets(\\>=100x10\\^9/L), blasts (0%) and no dysplasia\n* partial remission(PR) is the same as CR for peripheral blood: bone marrow shows blasts decrease by \\>=50% or a less advanced FAB classification from pretreatment\n* stable disease(SD) is a failure to achieve at least a partial remission, but with no evidence of progression for at least 2 months.","groups":[{"description":"Azacitidine, 75 mg/m\\^2/day given by subcutaneous injection for 7 days of every 28 day cycle, plus best supportive care.","id":"OG000","title":"Azacitidine"},{"description":"Physician choice of low dose cytarabine, standard chemotherapy, or best supportive care (consisting of blood products, growth factors, antibiotics)","id":"OG001","title":"Conventional Care"}],"paramType":"NUMBER","populationDescription":"Intent to treat population.","reportingStatus":"POSTED","timeFrame":"Day 1 to 42 months","title":"Number of Participants Considered Hematologic Responders by Investigator Determinations Using International Working Group (IWG 2000) Criteria for Myelodysplastic Syndrome (MDS)","type":"SECONDARY","unitOfMeasure":"participants"}